Sanja Glisic

List of Publications by Year
in descending order

55 papers	1,171 citations	430442 18 h-index	414034 32 g-index
61 all docs	61 docs citations	61 times ranked	1696 citing authors

#	Article	IF	Citations
1	An expanded evaluation of protein function prediction methods shows an improvement in accuracy. Genome Biology, 2016, 17, 184.	3.8	308
2	Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Structural Biology, 2009, 9, 21.	2.3	67
3	Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Structural Biology, 2009, 9, 62.	2.3	62
4	Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism. Vaccine, 2014, 32, 6569-6575.	1.7	51
5	Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method. Molecules, 2020, 25, 3830.	1.7	49
6	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 2015, 4, 34.	0.8	41
7	Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population. Clinica Chimica Acta, 2003, 327, 181-185.	0.5	37
8	Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1226-1232.	1.0	35
9	Discovery of New Therapeutic Targets by the Informational Spectrum Method. Current Protein and Peptide Science, 2008, 9, 493-506.	0.7	34
10	Novel Phylogenetic Algorithm to Monitor Human Tropism in Egyptian H5N1-HPAIV Reveals Evolution toward Efficient Human-to-Human Transmission. PLoS ONE, 2013, 8, e61572.	1.1	33
11	Natural Products as Promising Therapeutics for Treatment of Influenza Disease. Current Pharmaceutical Design, 2015, 21, 5573-5588.	0.9	27
12	The role of long-range intermolecular interactions in discovery of new drugs. Expert Opinion on Drug Discovery, 2011, 6, 1263-1270.	2.5	26
13	In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Frontiers in Microbiology, 2015, 6, 135.	1.5	24
14	Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets. Molecules, 2016, 21, 589.	1.7	24
15	Ibuprofen as a template molecule for drug design against Ebola virus. Frontiers in Bioscience - Landmark, 2018, 23, 947-953.	3.0	23
16	In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. F1000Research, 2015, 4, 104.	0.8	23
17	In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum. Molecules, 2018, 23, 772.	1.7	20
18	Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy. European Journal of Medicinal Chemistry, 2019, 181, 111580.	2.6	20

#	Article	IF	Citations
19	Demonstration of a Direct Interaction between β2-Adrenergic Receptor and Insulin Receptor by BRET and Bioinformatics. PLoS ONE, 2014, 9, e112664.	1.1	19
20	Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors. Frontiers in Cellular and Infection Microbiology, 2019, 9, 67.	1.8	19
21	Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease. Proteins: Structure, Function and Bioinformatics, 2008, 70, 855-862.	1.5	15
22	Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1. Scandinavian Journal of Medicine and Science in Sports, 2010, 20, 469-474.	1.3	15
23	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorganic and Medicinal Chemistry, 2016, 24, 3174-3183.	1.4	15
24	Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets. Molecules, 2019, 24, 1282.	1.7	15
25	Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic. Frontiers in Microbiology, 2015, 6, 1456.	1.5	13
26	Simple and General Criterion for "in silico" Screening of Candidate HIV Drugs. Current Pharmaceutical Biotechnology, 2013, 14, 561-569.	0.9	13
27	Critical Impact of Different Conserved Endoplasmic Retention Motifs and Dopamine Receptor Interacting Proteins (DRIPs) on Intracellular Localization and Trafficking of the D2 Dopamine Receptor (D2-R) Isoforms. Biomolecules, 2020, 10, 1355.	1.8	12
28	Preclinical discovery and development of maraviroc for the treatment of HIV. Expert Opinion on Drug Discovery, 2015, 10, 671-684.	2.5	11
29	Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR). Scientific Reports, 2019, 9, 16555.	1.6	11
30	Biological Rationale for the Repurposing of BCG Vaccine against SARS-CoV-2. Journal of Proteome Research, 2020, 19, 4649-4654.	1.8	11
31	Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy. PLoS ONE, 2011, 6, e28304.	1.1	8
32	Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. Protein Journal, 2012, 31, 129-136.	0.7	8
33	Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in Chronic Tinnitus. Frontiers in Neuroscience, 2017, 11, 636.	1.4	8
34	Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach**. ChemistryOpen, 2022, 11, e202100248.	0.9	8
35	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 0, 4, 34.	0.8	7
36	Functional characterization of β2-adrenergic and insulin receptor heteromers. Neuropharmacology, 2019, 152, 78-89.	2.0	6

#	ARTICLE	IF	CITATIONS
37	New in silico and conventional in vitro approaches to advance HIV drug discovery and design. Expert Opinion on Drug Discovery, 2013, 8, 83-92.	2.5	5
38	Feature-Based Classification of Amino Acid Substitutions outside Conserved Functional Protein Domains. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	5
39	Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3. BMC Bioinformatics, 2016, 17, 139.	1.2	5
40	AIDS vaccine: Efficacy, safety and ethics. Vaccine, 2008, 26, 3072-3077.	1.7	4
41	Apolipoprotein e gene polymorphism as a risk factor for ischemic cerebrovascular disease. Journal of Medical Biochemistry, 2004, 23, 255-264.	0.1	4
42	In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer's Disease. Molecules, 2022, 27, 2626.	1.7	4
43	Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?. Medical Hypotheses, 2011, 77, 404-408.	0.8	3
44	Natural autoantibodies in healthy neonatals recognizing a peptide derived from the second conserved region of HIV-1 GP120. Vojnosanitetski Pregled, 2014, 71, 352-361.	0.1	3
45	Improving attrition rates in Ebola virus drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 1025-1032.	2.5	3
46	In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. Frontiers in Neuroscience, 2016, 9, 520.	1.4	2
47	The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. Archives of Virology, 2016, 161, 1189-1198.	0.9	2
48	A simple method for calculation of basic molecular properties of nutrients and their use as a criterion for a healthy diet. F1000Research, 2017, 6, 13.	0.8	2
49	Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. PLoS ONE, 2016, 11, e0165451.	1.1	2
50	A Bioinformatics Approach to Identify Natural Autoantibodies from Healthy Blood Donors' Sera Reactive with the HCV NS5A-Derived Peptide by Immunoassay. Viral Immunology, 2011, 24, 69-76.	0.6	1
51	Design of targeting peptides for nanodrugs for treatment of infectious diseases and cancer. , 2018, , 343-381.		1
52	Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b. Archives of Biological Sciences, 2014, 66, 193-201.	0.2	1
53	Association of lipoprotein lipase gene Asn291Ser DNA polymorphism with plasma lipid levels and blood pressure levels in healthy population of Serbia. Journal of Medical Biochemistry, 2003, 22, 237-242.	0.1	1
54	*In vitro* Anti-influenza Activity of *in silico* Repurposed Candidate Drug Cycrimine. Antiviral Therapy, 2019, 24, 589-593.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Simple Chemoinformatics Criterion Using Electron Donor-Acceptor Molecular Characteristics for Selection of Antibiotics Against Multi-Drug-Resistant Bacteria. Discoveries, 2016, 4, e64.	1.5	0